Brief: Ceapro Inc Provides Update On Development Of An Inhalable Therapeutic For Covid-19

Ceapro

18/08/2020 13:36

Aug 18 (Reuters) - Ceapro Inc  CZO.V :
    * CEAPRO INC. PROVIDES UPDATE ON DEVELOPMENT OF AN INHALABLE
THERAPEUTIC FOR COVID-19
    * CEAPRO - IN-VITRO STUDY WITH HUMAN CELL LINES SHOWED
PGX-YBG
OBTAINED FROM DIFFERENT SOURCES EXHIBITED SIGNIFICANT
STIMULATORY EFFECT ON HUMAN IMMUNE RESPONSE
    * CEAPRO INC - EXPECTS PGX-YBG WILL STIMULATE HUMAN IMMUNE
RESPONSE ONCE INHALED INTO LUNGS & POTENTIALLY PREVENT REACTIONS
LIKE CYTOKINE STORM
    * CEAPRO INC - RESULTS DEMONSTRATED IN IN-VITRO STUDY WERE
CONSISTENT WITH RESULTS SEEN IN PRELIMINARY BIOLOGICAL STUDY
    * CEAPRO - PREPARATIONS OF A PHASE 1/2 CLINICAL TRIAL
PROTOCOL TO
BE COMMENCED IMMEDIATELY, PLANNED TO BE SUBMITTED TO HEALTH
AUTHORITIES DURING Q4 2020
    * CEAPRO - FIRST MILESTONE TO OPTIMIZE SIZE & MORPHOLOGY OF
BEST
PGX-YBG FOR IMMUNOMODULATION WAS FULLY ACHIEVED

Source text for Eikon:  ID:nGNX6NBX29 
Further company coverage:  CZO.V 

 ((Reuters.Briefs@thomsonreuters.com;))